SCHEMBL9997180

SCHEMBL9997180

O=C(O)c1cccc(NS(=O)(=O)c2cc(F)ccc2F)c1O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTK2B Q14289 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PFKFB3 Q16875 1/20 0.49
ACLY P53396 6/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 2/20 0.48
PFKFB4 Q16877 1/20 0.47
MCL1 Q07820 2/20 0.47
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
ALB P02768 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CCR2 P41597 1/20 0.45
FABP4 P15090 1/20 0.45
FABP5 Q01469 1/20 0.45
BCL2L1 Q07817 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9996881 0.81 ALDH1A1 (0.62) SMN1; SMN2PFKFB3ALDH1A1HSD17B10PFKFB4
SCHEMBL29721313 0.78 CYP3A4 (0.52) SMN1; SMN2ACLYCYP3A4FABP4
SCHEMBL29721254 0.78 CYP3A4 (0.52) SMN1; SMN2ACLYCYP3A4FABP4
SCHEMBL1127184 0.78 CYP3A4 (0.52) SMN1; SMN2ACLYCYP3A4FABP4
SCHEMBL787938 0.77 PFKFB3 (0.71) PFKFB3ACLYALDH1A1HSD17B10PFKFB4
SCHEMBL9997159 0.75 HSD17B10 (0.62) PTK2BPFKFB3ACLYALDH1A1HSD17B10
SCHEMBL28925258 0.75 MCL1 (0.56) PFKFB3ACLYALDH1A1HSD17B10MCL1
SCHEMBL28637555 0.75 KMT2A (0.58) PFKFB3ACLYALDH1A1HSD17B10MCL1
SCHEMBL2158732 0.73 IKBKB (0.60) ACLYMEN1KMT2A
SCHEMBL574453 0.73 PTGES2 (0.54) PTK2BSMN1; SMN2ACLYCYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed